Acuta Capital Acquires Stake in Erasca (ERAS) with $4.19 Million Share Purchase
On May 15, 2026, Acuta Capital Partners initiated a new position by purchasing 354,575 shares of Erasca (NASDAQ: ERAS), valued at approximately $4.19 million during the first quarter. The stake increased in value to an estimated $5.74 million as of March 31, 2026.
Tickers: $ERAS
Topics: biotech cancer treatments SEC filings stock ownership